GLP-1 medications, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), were originally developed for type 2 diabetes and later approved for chronic weight management at full therapeutic doses
Injectable GLP-1s may be more suitable for: Patients aiming for the maximum possible reduction in body weight, those with co-existing conditions like heart disease or chronic kidney disease (due to specific FDA approvals for Ozempic), or those who prefer a simple weekly medication schedule
[DOI] [PMC free article] [PubMed] [Google Scholar] 10.OECD The Heavy Burden of Obesety: The Economics of Prevention
proposed that in the initiation of HF, myocardial fatty acid, glucose, ketone body, and branched-chain amino acid metabolism is disturbed, leading to alterations in myocardial structure and function 26,40
Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al
It does this by reducing saliva production (hyposalivation), which can in turn lead to dry mouth (xerostomia)